roadest and most robust range of biologically-specific imaging readouts
in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense
(R), IntegriSense(TM), AngioSense(TM), OsteoSense
(R), MMPSense(TM), Cat-K FAST(TM), and now Annexin-Vivo. VisEn also offers specialized lines of
in vivo agent labeling platforms, including its proprietary VivoTag
(R) fluorescence labeling dyes for custom agent development and its NanoSpark
(R) labeling nanoparticles. They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in
in vivo imaging. All VisEn agents and labels, including the new
Annexin-Vivo 750 and
Cat-K FAST(TM) agents, are designed for
in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT
(TM)) imaging systems, or for general use along with other non-quantitative fluorescence
in vivo imaging systems. VisEn agents are also designed to enable complementary
in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.
About VisEn Medical Inc.
VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions an
'/>"/>
SOURCE VisEn Medical Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent2.
VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo3.
VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent4.
VisEn Medical Raises $7 Million in Series B Financing5.
VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent6.
Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States7.
OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells8.
Elsevier Global Medical News Launches H1N1 Channel9.
PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry10.
Surface Mount Solutions Launches New Website11.
One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions